![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAL |
Gene summary for MAL |
![]() |
Gene information | Species | Human | Gene symbol | MAL | Gene ID | 4118 |
Gene name | mal, T cell differentiation protein | |
Gene Alias | MVP17 | |
Cytomap | 2q11.1 | |
Gene Type | protein-coding | GO ID | GO:0001766 | UniProtAcc | A0A024RE19 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4118 | MAL | P23T-E | Human | Esophagus | ESCC | 4.29e-11 | 8.19e-01 | 0.108 |
4118 | MAL | P128T-E | Human | Esophagus | ESCC | 3.99e-07 | 9.11e-01 | 0.1241 |
4118 | MAL | S014 | Human | Liver | HCC | 1.15e-08 | 7.37e-01 | 0.2254 |
4118 | MAL | S015 | Human | Liver | HCC | 2.71e-07 | 8.24e-01 | 0.2375 |
4118 | MAL | S016 | Human | Liver | HCC | 7.18e-17 | 1.19e+00 | 0.2243 |
4118 | MAL | C43 | Human | Oral cavity | OSCC | 7.87e-03 | -1.70e-01 | 0.1704 |
4118 | MAL | LN22 | Human | Oral cavity | OSCC | 5.83e-06 | 2.19e+00 | 0.1733 |
4118 | MAL | SYSMH4 | Human | Oral cavity | OSCC | 4.35e-08 | 1.01e-01 | 0.1226 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00455802 | Prostate | BPH | regulation of T cell differentiation | 36/3107 | 146/18723 | 7.96e-03 | 3.47e-02 | 36 |
GO:0046632 | Prostate | BPH | alpha-beta T cell differentiation | 29/3107 | 112/18723 | 8.07e-03 | 3.51e-02 | 29 |
GO:19021074 | Prostate | BPH | positive regulation of leukocyte differentiation | 38/3107 | 157/18723 | 8.96e-03 | 3.83e-02 | 38 |
GO:19037084 | Prostate | BPH | positive regulation of hemopoiesis | 38/3107 | 157/18723 | 8.96e-03 | 3.83e-02 | 38 |
GO:19030399 | Prostate | BPH | positive regulation of leukocyte cell-cell adhesion | 54/3107 | 239/18723 | 9.57e-03 | 4.05e-02 | 54 |
GO:00024565 | Prostate | BPH | T cell mediated immunity | 28/3107 | 109/18723 | 1.02e-02 | 4.27e-02 | 28 |
GO:00022863 | Prostate | BPH | T cell activation involved in immune response | 29/3107 | 114/18723 | 1.04e-02 | 4.35e-02 | 29 |
GO:004209810 | Prostate | BPH | T cell proliferation | 46/3107 | 199/18723 | 1.05e-02 | 4.39e-02 | 46 |
GO:007121610 | Prostate | BPH | cellular response to biotic stimulus | 55/3107 | 246/18723 | 1.11e-02 | 4.55e-02 | 55 |
GO:190332019 | Prostate | Tumor | regulation of protein modification by small protein conjugation or removal | 92/3246 | 242/18723 | 1.20e-14 | 1.73e-12 | 92 |
GO:004586219 | Prostate | Tumor | positive regulation of proteolysis | 124/3246 | 372/18723 | 3.46e-14 | 4.31e-12 | 124 |
GO:005254719 | Prostate | Tumor | regulation of peptidase activity | 137/3246 | 461/18723 | 2.48e-11 | 1.71e-09 | 137 |
GO:003139619 | Prostate | Tumor | regulation of protein ubiquitination | 76/3246 | 210/18723 | 3.96e-11 | 2.68e-09 | 76 |
GO:000691316 | Prostate | Tumor | nucleocytoplasmic transport | 97/3246 | 301/18723 | 1.78e-10 | 1.05e-08 | 97 |
GO:005116916 | Prostate | Tumor | nuclear transport | 97/3246 | 301/18723 | 1.78e-10 | 1.05e-08 | 97 |
GO:004328119 | Prostate | Tumor | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 74/3246 | 209/18723 | 2.29e-10 | 1.33e-08 | 74 |
GO:005254819 | Prostate | Tumor | regulation of endopeptidase activity | 126/3246 | 432/18723 | 5.86e-10 | 3.01e-08 | 126 |
GO:200011619 | Prostate | Tumor | regulation of cysteine-type endopeptidase activity | 79/3246 | 235/18723 | 9.68e-10 | 4.66e-08 | 79 |
GO:004578519 | Prostate | Tumor | positive regulation of cell adhesion | 125/3246 | 437/18723 | 2.56e-09 | 1.08e-07 | 125 |
GO:001095219 | Prostate | Tumor | positive regulation of peptidase activity | 68/3246 | 197/18723 | 4.09e-09 | 1.66e-07 | 68 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAL | SNV | Missense_Mutation | c.88N>C | p.Glu30Gln | p.E30Q | P21145 | protein_coding | deleterious(0.01) | possibly_damaging(0.881) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
MAL | SNV | Missense_Mutation | rs745729561 | c.139C>T | p.Pro47Ser | p.P47S | P21145 | protein_coding | tolerated(0.1) | probably_damaging(0.988) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAL | SNV | Missense_Mutation | rs775300945 | c.428N>T | p.Ala143Val | p.A143V | P21145 | protein_coding | tolerated(0.05) | benign(0.426) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAL | SNV | Missense_Mutation | novel | c.254N>C | p.Val85Ala | p.V85A | P21145 | protein_coding | tolerated(0.47) | benign(0.243) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAL | SNV | Missense_Mutation | c.359G>T | p.Arg120Met | p.R120M | P21145 | protein_coding | deleterious(0.03) | benign(0.369) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MAL | SNV | Missense_Mutation | c.127T>A | p.Ser43Thr | p.S43T | P21145 | protein_coding | deleterious(0.02) | possibly_damaging(0.744) | TCGA-CM-6679-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
MAL | SNV | Missense_Mutation | rs749751444 | c.335N>T | p.Thr112Met | p.T112M | P21145 | protein_coding | tolerated(0.22) | benign(0.022) | TCGA-D5-6924-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MAL | SNV | Missense_Mutation | novel | c.145N>G | p.Pro49Ala | p.P49A | P21145 | protein_coding | tolerated(0.16) | benign(0.039) | TCGA-DM-A28F-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
MAL | SNV | Missense_Mutation | rs775300945 | c.428N>T | p.Ala143Val | p.A143V | P21145 | protein_coding | tolerated(0.05) | benign(0.426) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAL | SNV | Missense_Mutation | novel | c.89A>G | p.Glu30Gly | p.E30G | P21145 | protein_coding | deleterious(0) | probably_damaging(0.913) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |